Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 8/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | HRH2 | P25021 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405051 | 0.92 | — | — | |
| SCHEMBL5613588 | 0.82 | PTGS2 (0.35) | LMNATSHR | |
| Hydrochloric Acid SCHEMBL31645727 | 0.81 | CYP1A2 (0.33) | — | |
| SCHEMBL3401498 | 0.78 | LMNA (0.33) | LMNA | |
| SCHEMBL7648194 | 0.77 | SKP2 (0.31) | — | |
| SCHEMBL3405877 | 0.75 | — | — | |
| SCHEMBL4197781 | 0.72 | — | — | |
| SCHEMBL31646063 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL3693819 | 0.58 | — | — | |
| SCHEMBL14718645 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865924-B2 | Compounds for use as ligands | UNIVERSITY OF LEEDS (GB) | 2014-10-21 | — | — | US | claimed |
| US-8501829-B2 | Compounds for use as ligands | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2013-08-06 | — | — | US | claimed |
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| US-9399211-B2 | Microencapsulated catalyst-ligand system | REAXA LIMITED (GB) | 2016-07-26 | — | — | US | disclosed |
| US-20160030935-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | REAXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-8865924-B2 | Compounds for use as ligands | UNIVERSITY OF LEEDS (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20130267725-A1 | COMPOUNDS FOR USE AS LIGANDS | UNIVERSITY OF LEEDS (GB) | 2013-10-10 | — | — | US | disclosed |
| US-8501829-B2 | Compounds for use as ligands | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20090221419-A1 | Microencapsulated Catalyst-Ligand System | REAXA LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1993721-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | Reaxa Limited (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007096592-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | REAXA LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | SELL, SELE, NCL | HRH1 2623/4885CA12 178/4885CA1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.